and just to clarify, when I say that "I don't know how many 2b clinical trials in CKD are running or planned at the moment" I am referring to biotech and big pharma around the world...DXB, sitting on <$20M market cap and running 2 trials targeting separate CKD diagnosis has to attract some attention in the right places.
Ann: CMO Appointment and Clinical Trials Update, page-18
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.015(4.05%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.3¢ | $442.1K | 1.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 256045 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 16670 | 3 |
View Market Depth
| Last trade - 13.11pm 05/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |